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We investigated the inhibitory eﬀect of three glycyrrhizin derivatives, such as Glycyrrhizin (compound 1), dipotassium
glycyrrhizate (compound 2) and glycyrrhetinic acid (compound 3), on the activity of mammalian pols. Among these derivatives,
compound 3 was the strongest inhibitor of mammalian pols α, β, κ,a n dλ, which belong to the B, A, Y, and X families of
pols, respectively, whereas compounds 1 and 2 showed moderate inhibition. Among the these derivatives tested, compound 3
displayed strongest suppression of the production of tumor necrosis factor-α (TNF-α) induced by lipopolysaccharide (LPS) in a
cell-culture system using mouse macrophages RAW264.7 and peritoneal macrophages derived from mice. Moreover, compound 3
wasfoundtoinhibittheactionofnuclear factor-κB(NF -κB)inengineeredhumanembryonickidney(HEK)293cells.Inaddition,
compound3causedgreaterreductionof12-O-tetradecanoylphorbol-13-acetate-(TPA-)inducedacuteinﬂammationinmouseear
than compounds 1 and 2. In conclusion, this study has identiﬁed compound 3, which is the aglycone of compounds 1 and 2,a sa
promising anti-inﬂammatory candidate based on mammalian pol inhibition.
1.Introduction
The human genome encodes at least 15 DNA polymerases
(pols) that conduct cellular DNA synthesis [1, 2]. Eukaryotic
cells contain 3 replicative pols (α, δ,a n dε), 1 mitochondrial
pol (γ), and at least 11 nonreplicative pols [β, ζ, η, θ, ι,
κ, λ, μ, ν, terminal deoxynucleotidyl transferase (TdT) and
REV1] [3, 4]. Pols have a highly conserved structure, which
meansthattheiroverallcatalyticsubunitsshowlittlevariance
among species. Enzymes with conserved structures usually
perform important cellular functions, the maintenance of
which provides evolutionary advantages. On the basis of
sequence homology, eukaryotic pols can be divided into 4
m a i nf a m i l i e s ,t e r m e dA ,B ,X ,a n dY[ 4]. Family A includes
mitochondrialpolγ,aswellaspolsθ andν.FamilyBincludes
3 replicative pols (α, δ,a n dε)a n dp o lζ. Family X comprises
pols β, λ,a n dμ, as well as TdT, and lastly, family Y includes
pols η, ι,a n dκ, in addition to REV1.
We have been screening for selective inhibitors of each
pol derived from natural products, in particular from
traditional medical plants, food materials and food addi-
tives, for more than 15 years [5, 6]. Licorice (fabaceae
and glycyrrhiza), a well-known herb plant with biological
properties, has been widely used in food additives (sweetener2 Evidence-Based Complementary and Alternative Medicine
and ﬂavoring agent), nutraceuticals (liver protection), and
the treatment of various inﬂammatory diseases since ancient
times[7].LicoriceroothasbeenusedsinceancientEgyptian,
Greek, and Roman times in the West, and since the Former
Han era (the 2nd-3rd century B.C.) in ancient China in the
East. In traditional Chinese medicine, licorice is one of the
most frequently used drugs. There are many reports about
itspharmacologicalactionsandphysiologicalfunctions,such
as detoxiﬁcation, induction of decreased blood glucose, and
antitumor, anti-inﬂammatory, hypocholesterolemic, antie-
strogen, antihistamine, antiallergic hepatitis, antileukemia,
anticancer, and antibiotic-like eﬀects [8].
The seed stock of licorice (Glycyrrhiza glabra L.) has
6 varieties, and licorice production is widely distributed
over the Eurasian continent, South Europe, Central Asia,
China and Russia. In particular, G. inﬂata, G. uralensis,
and G. glabra are utilized in the production of sweeteners,
cosmetics, and medicines. The major constituents of licorice
root are triterpenoid saponins, such as glycyrrhizin (3–8%).
Glycyrrhizin (glycyrrhizic acid and glycyrrhizinic acid) is
a sweet-tasting compound, and is 30–50 times as sweet
as sucrose. Glycyrrhizin (compound 1) consists of one
molecule of glycyrrhetinic acid (compound 3) and two
molecules of glucuronic acid (Figure 1), and it is converted
to these constituents by acidic hydrolysis [9].
In our studies of pol inhibitors, we have found that
pol λ-selective inhibitors, such as curcumin derivatives
[10–12], have anti-inﬂammatory activity against 12-O-
tetradecanoylphorbol-13-acetate-(TPA-)inducedinﬂamma-
tion [13–15]. Although tumor promoters, such as TPA, are
classiﬁedascompoundsthatpromotetumorformation[16],
they also cause inﬂammation and are commonly used as
artiﬁcial inducers of inﬂammation in order to screen for
anti-inﬂammatory agents [17]. Tumor promoter-induced
inﬂammation can be distinguished from acute inﬂamma-
tion, which is exudative and accompanied by ﬁbroblast
proliferation and granulation. The tumor promoter TPA is
frequently used to search for new types of anti-inﬂammatory
compound. TPA not only causes inﬂammation, but also
inﬂuences mammalian cell growth [18], suggesting that the
molecularbasisoftheinﬂammationstemsfrompolreactions
relatedtocellproliferation.Thisrelationship,however,needs
to be investigated more closely.
Inthisstudy,wehaveinvestigatedtheinhibitoryeﬀectsof
glycyrrhizin (compound 1) and its derivatives, including the
potassium salt of compound 1 (dipotassium glycyrrhizate
and compound 2) and glycyrrhetinic acid (compound 3)
(Figure 1), on mammalian pol activity and inﬂammatory
responses both in vitro and in vivo.I np a r t i c u l a r ,w e
demonstrate that these compounds exert inhibitory eﬀects
against TNF-α production and NF-κBa c t i v a t i o ni nc e l l
culture models of inﬂammatory response. The relationship
between the inhibition of pols and the anti-inﬂammatory
action of the glycyrrhizin derivatives is discussed.
2.MaterialsandMethods
2.1. Materials. Glycyrrhizin (3-O-(2-O-β-D-glucopyranu-
ronosyl-α-D-glucopyranuronosyl)-18β-glycyrrhetinic acid,
compound 1), dipotassium glycyrrhizate (compound 2)
and glycyrrhetinic acid (compound 3) were obtained from
Maruzen Pharmaceuticals Co., Ltd. (Onomichi, Hiroshima,
Japan), and each compound was puriﬁed to special grade
purity. These structures are shown in Figure 1. Chemi-
cally synthesized DNA templates, such as poly(dA), was
purchased from GE Healthcare Bio-Sciences (Little Chal-
font, UK). Radioisotope-labeled nucleotides, such as [3H]-
deoxythymidine 5 -triphosphate (dTTP) (43Ci/mmol), was
purchased from MP Biomedicals, LLC (Tokyo, Japan). The
oligo(dT)18 DNA primer was customized by Sigma-Aldrich
JapanK.K.(Hokkaido,Japan).Lipopolysaccharide(LPS)and
T P Aw e r ep u r c h a s e df r o mS i g m a - A l d r i c h .A l lo t h e rr e a g e n t s
were of analytical grade and were purchased from Nacalai
Tesque Inc. (Kyoto, Japan).
2.2. Mammalian Pol Assays. Pol α was puriﬁed from calf thy-
mus by immunoaﬃnity column chromatography as de-
scribed by Tamai et al. [19]. The human pol γ catalytic
gene was cloned into pFastBac (Invitrogen Japan K.K., Tokyo
Japan). Histidine-tagged enzyme was expressed using the
BAC-TO-BAC HT Baculovirus Expression System according
to the supplier’s manual (Life Technologies, MD) and
puriﬁed using ProBound resin (Invitrogen Japan K.K.) [20].
A truncated form of pol κ (residues 1–560) with a 6xHis tag
attached at the C-terminus was overproduced in E. coli and
puriﬁed as described previously [21]. Recombinant human
His-pol λ was overexpressed and puriﬁed according to a
method described previously [22].
The reaction mixture for calf pol α was described previ-
ously [23, 24]. The reaction mixture for human pol γ was
previously described by Umeda et al. [20]. The reaction mix-
tures for mammalian pols κ and λ were the same as that for
calf pol α. The components of the pol assay were po-
ly(dA)/oligo(dT)18 (A/T = 2/1) and dTTP as the DNA
template-primer and 2 -deoxynucleoside 5 -triphosphate
(dNTP) substrate, respectively. The glycyrrhizin derivatives
(i.e., compounds 1–3) were dissolved in distilled dimethyl
sulfoxide (DMSO) at various concentrations and sonicated
for 30sec. The sonicated samples (4μL) were mixed with
16μL of each enzyme (ﬁnal amount, 0.05 units) in 50mM
Tris-HCl (pH 7.5) containing 1mM dithiothreitol, 50%
glycerol, and 0.1mM EDTA, and kept at 0◦C for 10min.
These inhibitor enzyme mixtures (8μL) were added to 16μL
of each of standard enzyme reaction mixture (50mM Tris-
HCl [pH 7.5], 1mM dithiothreitol, 1mM MgCl2, 15%
glycerol, 10μM poly(dA)/oligo(dT)18,a n d1 0 μM[ 3H]-
dTTP), and incubation was carried out at 37◦C for 60min.
Activity in the absence of inhibitor was considered to be
100%, and the activity remaining at each concentration of
inhibitor was determined relative to this value. One unit
of pol activity was deﬁned as the amount of enzyme that
catalyzed the incorporation of 1nmol dNTP (dTTP) into
the synthetic DNA template-primer (poly(dA)/oligo(dT)18,
A/T = 2/1) in 60min at 37◦C under normal reaction con-
ditions for each enzyme (scintillation counts: approximately
1pmol of incorporated radioactive nucleotide = 100cpm)
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Figure 1: Structure of the glycyrrhizin derivatives. (a) Glycyrrhizin (3-O-(2-O-β-D-glucopyranuronosyl-α-D-glucopyranuronosyl)-18β-
glycyrrhetinic acid; compound 1: R1 and R2 = H) and dipotassium glycyrrhizate (compound 2:R 1 and R2 = K+). (b) Glycyrrhetinic acid
(compound 3).
2.3. Animal Experiments. All animal studies were performed
according to the guidelines outlined in the “Care and Use of
Laboratory Animals” of Kobe University. The animals were
anesthetized with pentobarbital before undergoing cervical
dislocation. Female 8-week-old C57BL/6 mice that had been
bred in-house with free access to food and water were used
for all experiments. All of the mice were maintained under a
12-h light/dark cycle and housed at a room temperature of
25◦C.
2.4. Cell Culture. A mouse macrophage cell line, RAW264.7,
was obtained from American Type Culture Collection
(ATCC) (Manassas, Va, USA). The cells were cultured in
Eagle’s Minimum Essential Medium (MEM) supplemented
with 4.5g of glucose per liter plus 10% fetal calf serum,
5mML-glutamine, 50units/mL penicillin and 50units/mL
streptomycin. HEK-Blue hTLR4 cells were purchased from
InvivoGen (San Diego, Calif, USA), and were maintained
in complete Dulbecco minimal essential medium with
selective antibiotics, in accordance with the manufacturer’s
instructions (InvivoGen). The cells were cultured at 37◦Ci n
standard medium in a humidiﬁed atmosphere of 5% CO2–
95% air.
2.5. Preparation of Peritoneal Macrophages. Female C57BL/6
mice were injected intraperitoneally with phosphate-buﬀ-
ered saline (PBS), and the peritoneal cavity of the mice was
washed with PBS. The PBS was collected, and peritoneal ma-
crophages were separated from the PBS by centrifugation at
1,500 ×g for 10min.
2.6. Measurement of Cytotoxicity on a Cell-Culture Medium.
Approximately 1 × 104 cells per well were inoculated into
96-well microplates, and then compounds 1–3 were diluted
to various concentrations and applied to each well. After
incubation for 24h, the survival rate of RAW264·7c e l l s
was determined by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide) assay [25].
2.7. Measurement of TNF-α in a Cell-Culture Medium.
RAW264·7 cells or peritoneal macrophages were placed in
a 12-well plate at 5 × 104 cells/well and incubated for 24h.
The cells were pretreated with various concentrations of
compounds 1–3 for 30min before the addition of 100ng/mL
LPS. After stimulation with LPS for 24h, the cell culture
medium was collected to measure the amount of TNF-α4 Evidence-Based Complementary and Alternative Medicine
secreted. The concentration of TNF-α in the culture medium
was quantiﬁed by using a commercially available enzyme-
linked immunosorbent assay (ELISA) development system
(Bay Bioscience Co., Ltd., Kobe, Japan) in accordance with
the manufacturer’s protocol.
2.8. Measurement of the Nuclear Translocation of NF-κBi n
HEK293Cells. HEK-BluehTLR4cellsareengineeredhuman
embryonic kidney (HEK) 293 cells that stably coexpress
human Toll-like receptor 4 (TLR4) and an NF-κB-inducible
secreted embryonic alkaline phosphatase (SEAP) reporter
gene. These cells were placed in a 96-well plate at 1 ×
104 cells/well and incubated for 24h. The cells were pre-
incubated with various concentrations of compounds 1–
3 for 30min before the addition of 1ng/mL LPS. After
stimulation with LPS for 24h, NF-κB-induced SEAP activity
was assessed by using QUANTI-Blue (a medium used for
the detection and quantiﬁcation of SEAP; InvivoGen) and by
readingtheabsorbanceat650nmbymeansofanELISAplate
reader.
2.9. TPA-Induced Anti-Inﬂammatory Assay in Mouse. The
mouse inﬂammatory test was performed according to
Gschwendt’s method [26]. In brief, an acetone solution of
compounds 1–3 (250 or 500μgi n2 0μL) or 20μLo fa c e t o n e
asavehiclecontrolwasappliedtotheinnerpartofthemouse
ear. Thirty minutes after the test compound was applied, a
TPA solution (0.5μg/20μL of acetone) was applied to the
same part of the ear. To the other ear of the same mouse,
methanol,followedbyTPAsolution,wasappliedasacontrol.
After 7h, a disk (6mm diameter) was obtained from each
ear and weighed. The inhibitory eﬀect (IE) is presented as a
ratio of the increase in weight of the ear disks: IE: {[(TPA
only) − (tested compound plus TPA)]/[(TPA only) –
(vehicle)] × 100}.
3. Results
3.1. Eﬀect of Glycyrrhizin Derivatives (Compounds 1–3)o n
MammalianPolActivity. Initially,weinvestigatedtheinvitro
biochemical action of glycyrrhizin (compound 1) and its
derivatives (compounds 2 and 3). The inhibition of four
mammalian pols, namely, calf pol α,h u m a np o lγ,h u m a n
pol κ,a n dh u m a np o lλ,b ye a c hc o m p o u n da t2 0a n d
100μM was investigated. Pols α, γ, κ,a n dλ were used
as representatives of the B, A, Y, and X families of pols,
respectively [1–3]. As shown in Figure 2, at 100μM these
compounds inhibited the activity of all mammalian pols
tested,becausetherelativepolactivitywaslessthan50%after
incubation with these compounds. At 20μM, compound 3
also inhibited the activity of these pols, whereas compounds
1 and 2 had no eﬀect; therefore, the inhibitory eﬀect of
these compounds on mammalian pols was ranked as follows:
compound 3 > compound 1 = compound 2.C o m p o u n d3
showed almost the same strength of inhibition among the
four mammalian pols tested; that is, the concentration of
compound 3 giving 50% inhibition of pols α, γ, κ,a n dλ was
16.1, 19.3, 15.8, and 13.7μM, respectively. When activated
100 80 60 40 20 0
DNA polymerase activity (%)
2
0
μ
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0
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M
Compound 1
Compound 2
Compound 3
Compound 1
Compound 2
Compound 3
Calf pol α
Rat pol β
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Figure 2: Inhibitory eﬀects of glycyrrhizin derivatives (compounds
1–3) on the activity of mammalian pols. Each compound (20 and
100μM) was incubated with calf pol α (B-family pol), human pol
γ (A-family pol), human pol κ (Y-family pol), and human pol λ
(X-family pol) (0.05 units each). Pol activity in the absence of the
compound was taken as 100%, and the relative activity is shown.
Data are shown as the mean ± SE (n = 4).
DNA (i.e., bovine deoxyribonuclease I-treated DNA) and
dNTPwereusedastheDNAtemplate-primerandnucleotide
substrate instead of synthesized DNA [poly(dA)/oligo(dT)18
(A/T = 2/1)] and dTTP, respectively, the inhibitory eﬀects of
these compounds did not change (data not shown).
3.2. Inhibitory Eﬀect of Glycyrrhizin Derivatives (Compounds
1–3) on LPS-Induced Inﬂammatory Responses in Cultured
Cells. Next, we investigated whether the three glycyrrhizin
derivatives could inhibit both the reduction of TNF-α
productionandthenucleartranslocationofNF-κBcausedby
LPSstimulationinculturedcells.Theinﬂammatorycytokine
TNF-α activates the NF-κB signaling pathway by binding
to the TNF-α receptor (TNFR) and thereby initiates an
inﬂammatory response, resulting in various inﬂammatory
diseases [27]. In cultured macrophage RAW264.7 cells, no
compound showed cytotoxicity at 25 to 250μM( Figure 3);
therefore, the LD50 values of compounds 1–3 were >250μM.
These compounds also had no eﬀect on the cell proliferation
of peritoneal macrophages (data not shown). As shown in
Figure 4(a), RAW264.7 cells produced 693pg/mL of TNF-
α after LPS treatment. Compounds 1–3 slightly suppressed
this LPS-stimulated production of TNF-α, showing dose-
dependent inhibition at 100 and 200μM. The suppression of
TNF-α production by compound3was stronger than that by
compounds 1 and 2. Figure 4(b) shows the dose-dependent
suppression of LPS-evoked TNF-α production in peritonealEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Eﬀect of glycyrrhizin derivatives (compounds 1–3)
on the proliferation of the mouse macrophage RAW264.7 cell
growth. The cells were added the indicated concentrations of each
compound and incubated for 24h, and the rate of cultured cell
growth inhibition was determined by MTT assay [25]. Cell growth
inhibition of the cells in the absence of the compound was taken as
100%. Data are shown as the mean ± SE (n = 5).
macrophages derived from mice by the glycyrrhizin deriva-
tives. The inhibitory eﬀect of compounds 1–3 showed
almost the same tendency in peritoneal macrophages as in
the macrophage cell line RAW264.7 although compound
3 signiﬁcantly suppressed the production of TNF-α in
peritoneal macrophages. From these results, the strength of
the inhibitory eﬀect of these compounds can be ranked as
follows: compound 3 > compound 1 = compound 2.
NF-κB is known to be the rate-controlling factor
in inﬂammatory responses. We, therefore, examined the
inhibitory eﬀect of compounds 1–3 on the LPS-induced
nucleartranslocationofNF-κBinRAW264.7cells(Figure 5).
In this experiment, we used HEK-Blue hTLR4 cells, which
are HEK293 cells that have been engineered to report
TLR4-linked NF-κB activation. In brief, this cell line is
transfected with TLR4 and an NF-κB-inducible alkaline
phosphatase reporter gene system. On interaction with the
appropriate ligand, TLR4 transduces a signal that results in
NF-κB activation. In this assay system, the amount of NF-
κB undergoing nuclear translocation in the cells after LPS
stimulation was signiﬁcantly reduced by compound 3 at
100 and 200μM. By contrast, compounds 1 and 2 had no
eﬀect on the LPS-stimulated nuclear translocation of NF-
κB; thus, the ranking was compound 3   compound 1
= compound 2. These results demonstrate that compound
3 can strongly suppress the nuclear translocation of NF-
κB by inhibiting the production of TNF-α. The eﬀects
of glycyrrhizin derivatives on the molecular mechanism
underlying inﬂammatory responses will be addressed in
future studies.
3.3. Eﬀect of Glycyrrhizin Derivatives (Compounds 1–3)
on TPA-Induced Anti-Inﬂammatory Activity. In a previous
study of pol inhibitors, we found that there is a relationship
between pol λ inhibitors and TPA-induced acute anti-
inﬂammatory activity [6, 13, 14]. Thus, using the mouse
ear inﬂammatory test, we examined the anti-inﬂammatory
activity of the glycyrrhizin derivatives. Application of TPA
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Figure 4: Inhibitory eﬀects of glycyrrhizin derivatives (compounds
1–3) on LPS-induced production of TNF-α in mouse macrophages.
(a) The mouse macrophage cell line RAW264.7 was pretreated
with the indicated concentrations of the glycyrrhizin derivatives
for 30min, and then treated with 100ng/mL LPS for 24h. (b)
Peritoneal macrophages derived from mice were pretreated with the
indicated concentrations of each compound for 30min, and then
with 100ng/mL LPS for 24h. The TNF-α concentration in the cell
medium was measured by ELISA. Data are shown as the mean ± SE
(n = 5).
(0.5μg)tothemouseearinducededema,resultingina241%
increase in the weight of the ear disk 7h after application.
As shown in Figure 6, pretreatment with compounds 1–3
dose-dependently suppressed inﬂammation, and the eﬀect
of these compounds was ranked as follows: compound
3 > compound 1 = compound 2. Thus, these in vivo data
from the mouse ear study showed almost the same trend as
the LPS-induced inﬂammatory response data from cultured
cells (Figure 5). Furthermore, the anti-inﬂammatory eﬀect
of these compounds showed the same tendency as their
inhibitory eﬀect on mammalian pols including pol λ,w h i c h
was strongly inhibited by compound 3 (Figure 2). These
results suggest that inhibition of pol λ inhibitory activity
hasapositive correlationwiththeanti-inﬂammatory activity
observed.
4. Discussion
We have shown here that glycyrrhetinic acid (compound 3)
was the strongest inhibitor of mammalian pols α, γ, κ,a n dλ
(Figure 2), and this compound prevented the inﬂammatory
response among the three glycyrrhizin derivatives (com-
pounds 1–3) tested (Figures 4 to 6). Compound 3 is the agly-6 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Inhibitory eﬀects of glycyrrhizin derivatives (compounds
1–3) on nuclear translocation of NF-κB in engineered HEK293
cells. HEK-Blue hTLR4 cells were pretreated for 30min with the
indicated concentrations of the glycyrrhizin derivatives and then
treated with 1ng/mL LPS for 24h. NF-κB-induced SEAP activity
was assessed by using QUANTI-Blue and by reading the absorbance
at 650nm via an ELISA plate reader. Data are shown as the mean ±
SE (n = 5).
cone of compound 1, and the pentacyclic triterpenoid struc-
ture must be important for the inhibitory activity shown by
these compounds. Glycyrrhizin (compounds 1) and dipotas-
sium glycyrrhizate (compound 2), which is the dipotassium
salt of compound 1, are triterpenoid saponin glycosides, and
they both have two molecules of glucuronic acid (Figure 1).
Compound 2 is a major sweet-tasting food additive, and it is
5-fold sweeter than compound 1 [7]. The inhibitory eﬀect
of compound 1 on pol activity and inﬂammation showed
the same tendency as that of compound 2; therefore, the salt
formhadnoeﬀectontheinhibitoryactivitiesofglycyrrhizin.
Eukaryoticcellsreportedlycontain15polspeciesbelong-
ing to four families: namely, family A (pols γ, θ,a n dν),
family B (pols α, δ, ε,a n dζ), family X (pols β, λ,a n d
μ and TdT) and family Y (pols η, ι,a n dκ and REV1)
[3, 4]. As reported previously, the phenolic compound
curcumin, which is a known anti-inﬂammatory agent, is
ap o lλ-speciﬁc inhibitor [6, 13, 14]. Intriguingly, on the
basis of compound 3, the principle molecular target of the
glycyrrhizin derivatives is also pol λ. Among the X family of
pols, pol λ has an unclear biochemical function, although it
seems to work in a similar way to pol β [28]. Pol β is involved
in the short-patch base excision repair (BER) pathway [29–
32],aswellasplayinganessentialroleinneuraldevelopment
[33]. Recently, pol λ was found to possess 5 -deoxyribose-5-
phosphate (dRP) lyase activity, but no apurinic/apyrimidinic
(AP) lyase activity [34]. Pol λ is able to substitute for pol β
during in vitro BER, suggesting that pol λ also participates in
BER. Northern blot analysis indicated that transcripts of pol
β are abundantly expressed in the testis, thymus, and brain
in rats [35], whereas pol λ is eﬃciently transcribed mostly in
the testis [36]. Bertocci et al. reported that mice in which pol
λ expression is knocked out are not only viable and fertile,
but also display a normal hypermutation pattern [37].
Aswellascausinginﬂammation, TPAinﬂuencescellpro-
liferation and has physiological eﬀects on cells owing to
its tumor-promoting activity [18]. Therefore, anti-inﬂam-
matory agents are expected to suppress DNA replica-
tion/repair/recombination in nuclei in relation to the action
60 50 40 30 20 10 0
Anti-inﬂammatory eﬀect (%)
Compound 3
Compound 2
Compound 1
250μg/ear
500μg/ear
Figure 6: Anti-inﬂammatory activity of glycyrrhizin derivatives
towardTPA-inducededemaonmouseear.Eachcompound(250μg,
gray bar; and 500μg, black bar) was applied individually to one ear
of a mouse, and after 30min TPA (0.5μg) was applied to both ears.
Edema was evaluated after 7h. The inhibitory eﬀect is expressed as
a percentage of edema. Data are shown as the means ± SE (n = 6).
of TPA. Because pol λ is a repair/recombination-related
pol [28], our ﬁnding—that pol λ is the molecular target
of glycyrrhizin derivatives—is in good agreement with this
expected mechanism of anti-inﬂammatory agents. As a
result, any pol λ inhibitor might also be an inhibitor of
inﬂammation.
Compound 1 has been reported to possess various
pharmacological properties such as anti-inﬂammatory activ-
ity [38], inhibition of prostaglandin E2 production in rat
macrophages [39], antiallergic activity [40], antiviral activity
[41, 42], and induction of interferon-γ [43]. In Japan, a
preparation of compound 1, Stronger-Neo Minophagen C,
has been used extensively to treat chronic hepatitis for more
than 30 years. Compound 3 is also known to have wide
pharmacological eﬀects such as anti-inﬂammatory [44, 45],
antitumor[46],andantihepatotoxic[47]activities,andinhi-
bition of the growth of mouse melanoma [48]. In 1989, it
was reported that compound 3 strongly inhibits renal 11β-
hydroxysteroid dehydrogenase in rat [49]; this inhibition has
been regarded as a cause of the pseudoaldosteronism that is
occasionally induced by the administration of a compound
3 preparation or Carbenoxolone. However, the mechanisms
underlying the therapeutic eﬀects of the glycyrrhizin deriva-
tives remain unknown.
In this study, therefore, we investigated the inhibitory
eﬀect of the glycyrrhizin derivatives on mammalian pols,
which are responsible for DNA replication leading to cell
proliferation and DNA repair/recombination, as well as the
relationship between the degree of the suppression of LPS-
evoked TNF-α production and anti-inﬂammatory activity.
The molecular mechanism that links the LPS-induced in
ﬂammatory response and anti-inﬂammatory activity in the
model of TPA-induced ear edema is unknown. Because
activated NF-κB has been observed in a model of TPA-
induced ear edema [50], the anti-inﬂammatory eﬀects
of compound 3 may be, at least in part, dependent onEvidence-Based Complementary and Alternative Medicine 7
the inhibition of NF-κB activation. Our study indicates
that compound 3 is useful as an NF-κB inhibitor and may
be a potent chemopreventive agent against inﬂammation.
As a result, we found a positive correlation between the
pol inhibitory activity and anti-inﬂammatory activity of
compound 3. The relationship between these activities,
namely, pol λ inhibition and anti-inﬂammatory action, may
be useful as a new and convenient in vitro assay to screen for
novel anti-inﬂammatory compounds.
5. Conclusions
Our study is the ﬁrst to demonstrate that glycyrrhetinic acid
(compound 3), which is the aglycone of glycyrrhizin (com-
pounds 1), potently inhibited the activity of mammalian
pols including pol λ.C o m p o u n d3 also reduced TNF-α
production and NF-κB activation and suppressed mouse ear
inﬂammation stimulated by TPA. Thus, compound 3 could
be an anti-inﬂammatory agent based on pol λ inhibition.
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